Prins JM - Search Results

1

Patients' preferences regarding the timing of highly active antiretroviral therapy initiation for chronic asymptomatic HIV-1 infection.

Locadia M, van Grieken RA, Prins JM, de Vries HJ, Sprangers MA, Nieuwkerk PT. Locadia M, et al. Among authors: prins jm. Antivir Ther. 2006;11(3):335-41. Antivir Ther. 2006. PMID: 16759050

2

Improved long-term suppression of HIV-1 replication with a triple-class multidrug regimen compared with standard of care antiretroviral therapy.

van Praag RM, Wit FW, Jurriaans S, de Wolf F, Prins JM, Lange JM. van Praag RM, et al. Among authors: prins jm. AIDS. 2002 Mar 29;16(5):719-25. doi: 10.1097/00002030-200203290-00007. AIDS. 2002. PMID: 11964528

3

Persistence of viral HLA-DR- CD4 T-cell reservoir during prolonged treatment of HIV-1 infection with a five-drug regimen.

van Rij RP, van Praag RM, Prins JM, Rientsma R, Jurriaans S, Lange JM, Schuitemaker H. van Rij RP, et al. Among authors: prins jm. Antivir Ther. 2002 Mar;7(1):37-41. Antivir Ther. 2002. PMID: 12008786

4

Lettinga KD, Verbon A, Nieuwkerk PT, Jonkers RE, Gersons BP, Prins JM, Speelman P. Lettinga KD, et al. Among authors: prins jm. Clin Infect Dis. 2002 Jul 1;35(1):11-7. doi: 10.1086/340738. Epub 2002 Jun 7. Clin Infect Dis. 2002. PMID: 12060869

5

Dynamics of the pool of infected resting CD4 HLA-DR- T lymphocytes in patients who started a triple class five-drug antiretroviral regimen during primary HIV-1 infection.

Sankatsing SU, van Praag RM, van Rij RP, Rientsma R, Jurriaans S, Lange JM, Prins JM, Schuitemaker H. Sankatsing SU, et al. Among authors: prins jm. Antivir Ther. 2003 Apr;8(2):137-42. Antivir Ther. 2003. PMID: 12741626

6

Virologic and immunologic response to highly active antiretroviral therapy in indigenous and nonindigenous HIV-1-infected patients in the Netherlands.

Nellen JF, Wit FW, De Wolf F, Jurriaans S, Lange JM, Prins JM. Nellen JF, et al. Among authors: prins jm. J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):943-50. doi: 10.1097/00126334-200408010-00008. J Acquir Immune Defic Syndr. 2004. PMID: 15220701

7

Highly active antiretroviral therapy with or without mycophenolate mofetil in treatment-naive HIV-1 patients.

Sankatsing SU, Jurriaans S, van Swieten P, van Leth F, Cornelissen M, Miedema F, Lange JM, Schuitemaker H, Prins JM. Sankatsing SU, et al. Among authors: prins jm. AIDS. 2004 Sep 24;18(14):1925-31. doi: 10.1097/00002030-200409240-00008. AIDS. 2004. PMID: 15353978 Clinical Trial.

8

Safety of long-term interruption of successful antiretroviral therapy: the ATHENA cohort study.

Wit FW, Blanckenberg DH, Brinkman K, Prins JM, van der Ende ME, Schneider MM, Mulder JW, de Wolf F, Lange JM; ATHENA Study Group. Wit FW, et al. Among authors: prins jm. AIDS. 2005 Feb 18;19(3):345-8. AIDS. 2005. PMID: 15718848

9

Analysis of the effect of highly active antiretroviral therapy during acute HIV-1 infection on HIV-specific CD4 T cell functions.

Jansen CA, De Cuyper IM, Steingrover R, Jurriaans S, Sankatsing SU, Prins JM, Lange JM, van Baarle D, Miedema F. Jansen CA, et al. Among authors: prins jm. AIDS. 2005 Jul 22;19(11):1145-54. doi: 10.1097/01.aids.0000176214.17990.94. AIDS. 2005. PMID: 15990567

10

Short communication: No detrimental immunological effects of mycophenolate mofetil and HAART in treatment-naive acute and chronic HIV-1-infected patients.

Vrisekoop N, Sankatsing SU, Jansen CA, Roos MT, Otto SA, Schuitemaker H, Lange JM, Prins JM, Miedema F. Vrisekoop N, et al. Among authors: prins jm. AIDS Res Hum Retroviruses. 2005 Dec;21(12):991-6. doi: 10.1089/aid.2005.21.991. AIDS Res Hum Retroviruses. 2005. PMID: 16379601 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

496 results

Search Page

Filters